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Abstract
 
In many cases, induction of CD8
 
1
 
 CTL responses requires CD4
 
1
 
 T cell help. Recently, it has
been shown that a dominant pathway of CD4
 
1
 
 help is via antigen-presenting cell (APC) acti-
vation through engagement of CD40 by CD40 ligand on CD4
 
1
 
 T cells. To further study this
three cell interaction, we established an in vitro system using dendritic cells (DCs) as APCs and
influenza hemagglutinin (HA) class I and II peptide–specific T cell antigen receptor transgenic
T cells as cytotoxic T lymphocyte precursors and CD4
 
1
 
 T helper cells, respectively. We found
that CD4
 
1
 
 T cells can provide potent help for DCs to activate CD8
 
1
 
 T cells when antigen is
provided in the form of either cell lysate, recombinant protein, or synthetic peptides. Surpris-
ingly, this help is completely independent of CD40. Moreover, CD40-independent CD4
 
1
 
help can be documented in vivo. Finally, we show that CD40-independent T cell help is de-
livered through both sensitization of DCs and direct CD4
 
1
 
–CD8
 
1
 
 T cell communication via
lymphokines. Therefore, we conclude that CD4
 
1
 
 help comprises at least three components:
CD40-dependent DC sensitization, CD40-independent DC sensitization, and direct lympho-
kine-dependent CD4
 
1
 
–CD8
 
1
 
 T cell communication.
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1
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1
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Introduction
 
CD4
 
1
 
 T cells are essential for induction of CD8
 
1
 
 CTL re-
sponses against many cell-based antigens, including male-
specific antigen, model antigens loaded into splenocytes, or
tumor antigen transfected into cell lines (1–4). Many cell-
based antigens have been proven to activate CD8
 
1
 
 CTLs
through the cross-priming pathway, which involves bone
marrow–derived APCs that take up exogenous antigens
and present them via the MHC class I pathway (5, 6).
Thus, CD4
 
1
 
 T cells are also essential for in vivo cross-
priming (3, 4). However, only some viruses require CD4
 
1
 
T cells to induce CD8
 
1
 
 CTL responses (7–9); others do
not (10–12). Viruses that illicit helper-independent CTL
responses likely produce high epitope densities, probably
via infection of APCs leading to direct access of antigen to
the MHC class I processing pathway.
The role of CD4
 
1
 
 T cells was originally thought to be
the provision of cytokines such as IL-2 to facilitate activa-
tion, survival, and clonal expansion of CD8
 
1
 
 T cells (1).
Recent reports have suggested an alternative model involv-
ing APC sensitization by CD4
 
1
 
 T cells, demonstrating that
ligation of the TNFR family member, CD40, on APCs can
completely replace the necessity for CD4
 
1
 
 help (4, 13–15).
Ridge et al. (14) showed that either ligation of CD40 with
an agonist anti-CD40 antibody or incubation with antigen-
specific CD4
 
1
 
 T cells can activate DCs to a state in which
they are able to prime naive CD8
 
1
 
 T cells and activate
memory CD8
 
1
 
 T cells. Schoenberger et al. (4) and Bennett
et al. (15) used in vivo cross-priming models to demon-
strate that ligation of CD40 can completely restore CD8
 
1
 
CTL activities in CD4
 
1
 
 T cell–depleted mice. These re-
sults suggest that the dominant pathway by which CD4
 
1
 
 T
cells assist in CD8
 
1
 
 CTLs is via the engagement of CD40
on the surface of APCs. To further dissect the mechanism
by which CD4
 
1
 
 cells provide help for CD8
 
1
 
 T cell activa-
tion, we developed an in vitro system using dendritic cells
(DCs)
 
1
 
 as APCs and influenza hemagglutinin (HA) class I
and II peptide–specific TCR transgenic (Tg) T cells as
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CD40-independent Pathways of T Cell Help
 
CTL precursors (CTLs) and CD4
 
1
 
 helper cells, respec-
tively. We also examined the pathways of CD4
 
1
 
 T cell
help for priming CD8
 
1
 
 CTLs in vivo. Our findings dem-
onstrate that in addition to CD40-dependent DC sensitiza-
tion, CD40-independent DC sensitization and direct, lym-
phokine-dependent CD4
 
1
 
–CD8
 
1
 
 T cell communication
represent important components of CD4
 
1
 
 help for priming
of CD8
 
1
 
 CTLs.
 
Materials and Methods
 
Mice.
 
6–8-wk-old inbred BALB/c mice were obtained from
the National Cancer Institute, National Institutes of Health (Fred-
erick, Maryland). TCR Tg mice expressing an 
 
a
 
/
 
b
 
 TCR specific
for amino acids 110–120 from influenza HA presented by I-E
 
d
 
(6.5) were the gift of Dr. Harald von Boehmer, Harvard Univer-
sity, Boston, MA (16). TCR Tg mice expressing an 
 
a
 
/
 
b
 
 TCR
specific for amino acids 518–527 from influenza HA presented by
K
 
d
 
 (clone 4) were the gift of Dr. Linda Sherman, Scripps Research
Institute, La Jolla, CA (17). Clone 4 mice were also crossed with
Thy1.1
 
1
 
/
 
1
 
 BALB/c mice to obtain Thy1.1
 
1
 
/
 
2
 
TCR
 
1
 
/
 
2 
 
mice. Tg
mice used in these experiments were heterozygous for the trans-
gene. CD40-deficient (CD40
 
2
 
/
 
2
 
) mice in BALB/c background
were purchased from The Jackson Laboratory. All experiments in-
volving the use of mice were performed in accordance with proto-
cols approved by the Animal Care and Use Committee of the
Johns Hopkins University School of Medicine.
 
DC Preparation.
 
Bone marrow–derived DCs were prepared
according to a previously described protocol (18). In brief, bone
marrow was obtained from tibia and femurs by flushing media
through. After lysis of red blood cells, cells were resuspended at
10
 
6
 
 cells in RPMI 1640 supplemented with 5% FBS, 
 
l
 
-glutamine
(2 mM), penicillin/streptomycin (50 U/ml), 10% nonessential
amino acids, and 50 mM 2-ME plus 1,000 U/ml of recombinant
GM-CSF (provided by Immunex). 1 ml of cells was then plated
per well in 24-well plates and incubated at 37
 
8
 
C, 5% CO
 
2
 
. Fresh
GM-CSF–supplemented medium was added on days 2 and 4,
and loosely adherent cells on day 6 were transferred from tightly
adherent cells to 10-cm petri dishes. A second transfer was done
on day 7, and cells were collected on day 8. To enrich day 6
DCs, these loosely adherent cells (some of them forming clumps)
were loaded on the top of a 50% FBS gradient column in 15-ml
conical tubes to allow cell clumps to sediment. After a 30-min in-
cubation at 4
 
8
 
C, the top half of the column was removed and
cells at the bottom part of the column were collected by centrifu-
gation and used as day 6 DCs. About 50–70% of day 8 DCs ex-
press MHC II
 
high
 
B7-2
 
high
 
, and 20–30% express MHC II
 
low
 
B7-
2
 
low
 
. The expression levels of these molecules are lower in day 6
DCs. Splenic DCs were isolated according to a standard protocol
(19). In brief, spleens were digested with collagenase D (Boeh-
ringer Mannheim), splenocytes were centrifuged on BSA col-
umn (3220-75; Intergen), and low density splenocytes were ob-
tained. 10
 
7
 
 cells were plated into 60-mm tissue culture dishes and
incubated at 37
 
8
 
C for 90 min. Nonadherent cells were thor-
oughly washed away, and remaining adherent cells were incu-
bated at 37
 
8
 
C overnight. Detached nonadherent cells were then
collected as splenic DCs. Almost all of the cells expressed MHC
II
 
high
 
, B7-2
 
high
 
, B220
 
2
 
.
 
Antigens.
 
The CT26 mouse colon carcinoma cell line was
transfected with the full-length HA gene encoding HA protein of
influenza virus A/PR/8/34 (CT26-HA). CT26-HA was grown
as an adherent population under selection of G418 (400 
 
m
 
g/ml).
 
About 75% of the cells express HA protein on the surface as
shown by FACS
 
®
 
 analysis. CT26-HA lysate was prepared ac-
cording to a previously described protocol (20). In brief, cells
were scraped off the flask and hypotonically lysed in 5P8 buffer
(5 mM sodium phosphate, pH 8) for 10 min. Cells were soni-
cated and centrifuged at 5,000 rpm for 15 min to remove nuclei
from the low-speed spin. The supernatant was collected and re-
centrifuged at 15,000 rpm for 1 h. The supernatant from this
high-speed spin was discarded, and the pellet was resuspended in
a volume equivalent to 
 
z
 
3–4 
 
3
 
 10
 
7
 
 cells/ml. To prepare recom-
binant HA protein, the full-length HA DNA was cloned into the
pTrcHis vector (Invitrogen), and protein expression was induced
by adding isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG, 2 mM).
HA protein was then purified using Qiagen Ni-NTA agarose kit
and dialyzed in 1
 
3
 
 PBS. HA
 
110–120
 
 peptide (class II) and HA
 
518–527
 
peptide
 
 
 
(class I) were synthesized by Macromolecular Resources
and dissolved in 1
 
3
 
 HBSS at a concentration of 1 mg/ml.
 
Viruses.
 
A recombinant vaccinia virus encoding HA (vac-HA)
or nuclear protein (vac-NP, V69) from influenza virus A/PR/8/34
was a gift of Dr. Jack Bennick and Jonathan Yewdell, NIAID, Na-
tional Institutes of Health. Viruses were expanded on Hu-TK
 
2
 
cells in the presence of 5-bromo-2
 
9
 
-deoxyuridine (Sigma Chemi-
cal Co.) at 25 
 
m
 
g/ml, purified from the cellular lysate by sucrose
banding, and titered by plaque assay on B-SC-1 cells. 10
 
7
 
 PFU of
vac-HA or vac-NP were used for in vivo priming.
 
Enrichment of CD4
 
1
 
 and CD8
 
1
 
 T Cells.
 
Spleen and lymph
nodes from either naive CD4
 
1
 
 TCR Tg mice (6.5), CD8
 
1
 
 TCR
Tg mice (clone 4), or wild-type mice were collected, and single
cell suspensions were prepared through nylon mesh. After lysis of
red blood cells, cells were resuspended in 10 ml of 1
 
3
 
 HBSS
containing 2% FBS. To purify clone 4 CD8
 
1
 
 T cells, a mixture
of biotinylated antibodies (5–10 
 
m
 
g/ml) against MHC class II
(14.4.4; American Type Culture Collection), B220 (B220b;
PharMingen), and CD4 (L3T4/MR4-4; PharMingen) was added
to deplete MHC class II
 
1
 
 cells, B cells, and CD4
 
1
 
 T cells, respec-
tively. To purify 6.5 CD4
 
1
 
 T cells, the biotinylated 14.4.4b,
B220b, and anti-CD8 (ly-2; PharMingen) antibodies were added
to deplete MHC class II
 
1
 
 cells, B cells, and CD8
 
1
 
 T cells. Cells
were then incubated on a rocker at 4
 
8
 
C for 30 min and washed
three times with 1
 
3
 
 HBSS (2% FBS) at the end of the incubation.
Cells were then mixed with 3–4 
 
3
 
 10
 
8
 
 prewashed streptavidin
beads (Dynal) in 50-ml conical tubes to a final volume of 10 ml,
tubes were then rocked at 4
 
8
 
C for 1 h. At the end of the incuba-
tion, the tube was placed onto the magnet rack (Dynal) for 15 min
at 4
 
8
 
C. This procedure was repeated for a second time on nonmag-
netized cells. Twice-enriched CD4
 
1
 
 or CD8
 
1
 
 T cells were 85–94%
pure, containing 33% (6.5
 
1
 
CD4
 
1
 
) and 100% (V
 
b
 
8.2
 
1
 
CD8
 
1
 
) clo-
notypic T cells, respectively, as shown by FACS
 
®
 
 analysis.
 
Proliferation Assay.
 
3–5 
 
3
 
 10
 
4
 
 DCs were placed in triplicate
into 96-well U-bottomed plates, and cells were loaded with a se-
rial dilution of tumor lysate or synthetic HA class I or II peptide
for 6–12 h. After two to three washes with CTL medium (RPMI
1640 supplemented with 10% FBS, 2 mM 
 
l
 
-glutamine, 50 U/ml
penicillin/streptomycin, 10% nonessential amino acids, and 50 mM
2-ME), 3 
 
3
 
 10
 
4
 
 purified naive Tg CD41 T cells were added. 48 h
after adding T cells, [3H]thymidine (1 mCi/well; Amersham
Pharmacia Biotech) was added to each well. Cells were harvested
10–12 h later with a Packard Micromate cell harvester. [3H]Thy-
midine incorporation into DNA was measured as counts per
minute on a Packard Matrix 96 direct beta counter.
Enzyme-linked Immunospot Assay. A 96-well filtration plate
(Millipore) was coated with 10 mg/ml of anti–IFN-g antibody
(PharMingen) overnight. The wells were washed with PBST543 Lu et al.
(PBS containing 0.05% Tween 20) and blocked with culture me-
dium for 1 h. 3 3 105 splenocytes from viral infected mice were
plated into each well in the presence or absence of 1 mg/ml NP-Kd
peptide and incubated at 378C overnight. The plate was then
washed with PBST to thoroughly remove splenocytes and incu-
bated with 5 mg/ml biotinylated IFN-g antibody (PharMingen)
at 48C overnight. After washing with PBST, 1 mg/ml of alkaline
phosphatase–conjugated streptavidin (Jackson ImmunoResearch
Labs) was added to each well and the plate was incubated at room
temperature for 2 h. Spots were developed by adding 100 ml of
BCIP/NBT solution (Sigma Chemical Co.) and incubating at
room temperature for 10–20 min. Images of the spots were cap-
tured by CCD video camera and counted. The number of pep-
tide-specific IFN-g–positive spots was obtained by subtracting
the number of spots in the no peptide group from the number of
spots in the peptide group.
In Vitro CD41 Helper System. 3–5 3 104 day 6–8 bone mar-
row–derived DCs or splenic DCs were first plated in triplicate in
96-well U-bottomed plates and then loaded with serial dilutions
of either CT26-HA tumor lysate, recombinant HA protein, or
synthetic HA class I peptide together with a constant amount of
HA class II peptide (3.3 mg/ml). 3–5 3 104 cell equivalents of ly-
sate were used for 1:1 dilution. After 6–12 h incubation, cells
were washed two to three times with CTL medium, and 3–5 3
104 purified naive HA-specific Tg CD81 T cells plus either 3–5 3
104 naive HA-specific Tg or control non-Tg CD41 T cells were
added to each well. After 3 d incubation at 378C, 5% CO2, cells
from each well were split into two V-bottomed wells. 51Cr-
labeled P815 target cells, pulsed with HA class I peptide or un-
pulsed, were added to each of the two wells and incubated at
378C for 4 h. Released 51Cr activity was then measured by
gamma counter. Percent specific lysis was calculated as (sample
cpm – spontaneous cpm)/(maximum cpm – spontaneous cpm) 3
100. Percent peptide-specific lysis was calculated as (percent spe-
cific lysis of P815 cells pulsed with peptide) 2 (percent specific
lysis of unpulsed P815 cells).
In Vivo CD41 Helper System. 3  3 106 purified clonotypic
CD81 T cells (Thy1.11/2) were transferred intravenously with or
without 2.5 3 106 purified clonotypic 6.5 CD41 T cells to
BALB/c wild-type or CD402/2 BALB/c mice. 24 h later, mice
were infected intraperitoneally with 107 PFU of vac-HA. 4 d af-
ter infection, spleens were removed and single cell suspensions
were prepared. Cells were stained with PE-conjugated Thy1.1
and FITC-conjugated CD8 antibodies and analyzed by FACS®.
Double-positive populations represent the clonotypic CD81 T
cells. The second approach involved in vivo depletion of CD41
T cells in BALB/c wild-type or CD402/2 mice with 100 mg
GK1.5 given intraperitoneally every other day for 1 wk followed
by intraperitoneal infection with 107 PFU vac-NP. 7 d later, en-
zyme-linked immunospot (ELISPOT) assays for activated CD81
T cells were performed as described above, and T cells were re-
stimulated with NP-Kd peptide for an additional 6–7 d followed
by 51Cr-release assay.
In Vitro Sensitization of DCs and Activation of CD81 T Cells.
1–2 3 106 day 6 enriched DCs were plated in 24-well plates, and
CT26-HA lysate was added (1–2 3 106 cell equivalents). 6 h
later, 2 3 106 purified HA-specific or nonspecific CD41 T cells
were added and incubated for an additional 24–36 h. To remove
CD41 T cells from these cultures, cells were recovered from the
24-well plate and washed twice with 13 HBSS, and 10 mg/ml of
biotinylated antibody against CD4 (L3T4 MR44-4; PharMingen)
was added. Cells were incubated on a rocker at 48C for 30 min,
washed three times with 13 HBSS buffer, and mixed with
streptavidin-conjugated beads (Dynal) previously washed with
13 HBSS. Cells were incubated on the rocker for 1 h and recov-
ered by placing the tube on the magnet rack twice for 15 min
each. Cells were stained with the same biotinylated antibody fol-
lowed by PE-conjugated streptavidin to verify complete removal.
Separated DCs were then incubated with 3 3 104 naive Tg HA-
specific CD81 T cells with or without supernatant from activated
Tg CD41 T cells for 3 d. Percent peptide-specific lysis was deter-
mined from a 4-h 51Cr-release assay. In parallel, 5 3 104 DCs
were directly plated in triplicate into 96-well U-bottomed plates
and loaded with CT26-HA lysate (5 3 104 cell equivalents) for 6 h.
5  3 104 purified naive Tg CD41 T cells or control non-Tg
CD41 T cells were added to each well. After a 24-h culture, cells
were washed and 3 3 104 HA-specific Tg CD81 T cells were
added and incubated for 3 d. Percent peptide-specific lysis was
determined as above.
Flow Cytometric Analysis. DCs were stained with antibodies
against MHC class I (28-8-4S; American Type Culture Collec-
tion), MHC class II (14.44; American Type Culture Collection)
followed by FITC-conjugated goat anti–mouse IgG2a (Southern
Biotechnology), CD80/86 (CTLA-4Ig) followed by PE-conju-
gated goat anti–human IgG, CD40 (3/23; PharMingen) followed
by PE-conjugated goat anti–rat IgG, or CD11c (biotinylated
N418; PharMingen) followed by PE-conjugated streptavidin
(Caltag). HA-specific CD41 TCR Tg T cells (6.5) were double-
stained with FITC-conjugated goat anti–mouse CD4 (Caltag)
and biotinylated rat anti-clonotypic TCR antibody mAb 6.5 fol-
lowed by PE-conjugated streptavidin (Caltag). HA class I–specific
CD81 TCR Tg T cells were stained with PE-conjugated Thy1.1
(PharMingen) and FITC-conjugated CD8 (PharMingen). Cells
were collected on a FACScan™ (Becton Dickinson) and ana-
lyzed using CELLQuest™ software (Becton Dickinson).
Measurement of Cytokines. IL-2 and IFN-g were measured us-
ing an ELISA kit from R&D Systems.
Statistical Analysis. Two-way analysis of variance (Student’s t
test) was used to evaluate the difference between clonal expan-
sion of Thy1.11CD81 T cells in wild-type and CD402/2 mice
transferred with or without 6.5 CD41 Tg T cells.
Results
CD41 T Cells Can Provide Potent Help for DCs to Cross-
Prime and Direct-Prime CD8 T Cells. CD41 T cells have
been shown to be important for in vivo cross-priming (10).
In vitro studies using antigens such as OVA have demon-
strated CD4-independent cross-priming but only at exces-
sive concentrations of antigen (21–25), although the effi-
ciency of cross-priming may be increased by incorporation
of antigen into apoptotic bodies (26) or complexing with
heat shock proteins (27). To further study the role of
CD41 T cells in cross-priming, we established an in vitro
system in which bone marrow–derived DCs were used as
APCs and CD41 and CD81 TCR Tg T cells specific to in-
fluenza HA were used as T helper cells and CD81 CTLs,
respectively. When DCs were loaded with different con-
centrations of lysate from a tumor expressing HA (CT26-
HA), antigen-specific CD41 T cells (6.5) provided potent
help activating CD81 CTLs, even at relatively low antigen
doses, whereas non-Tg CD41 T cells failed to do so (Fig. 1
A). At high doses of HA in the form of lysate (.10:1 lysate/
DC ratio by cell equivalents), CD4-independent CD81 T544 CD40-independent Pathways of T Cell Help
cell activation was observed (data not shown), indicating
that antigen-specific CD41 T cell help shifted the antigen
dose–response curve for CD81 T cell activation z100-
fold. Similar results were obtained when recombinant HA
protein was used (Fig. 1 B). Similar phenomena can be
demonstrated using splenic DCs (data not shown). To de-
termine whether this effect is unique to cross-priming, we
pulsed splenic DCs with serial dilutions of the minimal cog-
nate MHC class I–restricted peptide (thereby bypassing an-
tigen processing) and a constant amount of the cognate HA
class II peptide in the presence or absence of antigen-spe-
cific CD41 T cells (Fig. 2, A and B). We found that in the
range of 10 mg/ml to 1 ng/ml, DCs activate CD81 CTLs at
equivalent plateau levels with or without CD41 help.
However, at HA class I peptide concentrations ,1 ng/ml,
HA-specific T cell help significantly enhanced CD81 T
cell activation, shifting the dose–response curve 3 logs and
allowing priming of naive CD81 T cell activation in the
femtomolar range of antigen. Not unexpectedly, direct in-
fection of DCs with recombinant vac-HA, which produces
high levels of MHC class I loading directly through the en-
dogenous pathway, efficiently stimulated CD81 T cells in
the absence of CD41 T helper cells (data not shown).
In Vitro CD41 Help for CTL Activation Is CD40 Indepen-
dent. To address whether CD40 is important for in vitro
CD41 help, we first evaluated its necessity for activating
naive Tg CD41 T cells. We found that naive Tg CD41 T
cells were activated equivalently by wild-type and CD402/2
DCs as measured by antigen-specific proliferation or lym-
phokine release (Fig. 3). Naive Tg CD81 T cells were also
equivalently activated by wild-type and CD402/2 DCs
pulsed with synthetic HA class I peptide (data not shown).
Most importantly, CD41 help for CTL activation was me-
diated equivalently by wild-type and CD402/2 DCs (Fig.
4). Furthermore, agonist anti-CD40 antibody failed to re-
place CD41 T cells (data not shown). Therefore, the help for
CD81 CTL priming in this in vitro system was completely
CD40 independent.
Evidence for CD40-independent CD41 T Cell Help In Vivo.
Given the clear in vitro evidence of CD40-independent
help for CD81 CTLs, we determined whether this could
be demonstrated in vivo. We initially examined the response
of adoptively transferred Tg T cells to infection with vac-HA
(Fig. 5). The clonal expansion of HA-specific TCR Tg
CD81 T cells was analyzed in the presence or absence of
adoptively transferred HA-specific Tg CD41 T cells. In
Figure 1. Effect of CD41 T cell help for cross-priming CD81 CTLs in
vitro. Bone marrow–derived DCs (day 6–8) were incubated with (A) tu-
mor lysate of CT26 expressing influenza HA antigen (CT26-HA) or (B)
recombinant HA protein for 6–12 h and then washed. Purified naive
HA-specific CD41 TCR Tg T cells (6.5) or non-Tg (N-Tg) CD41 T
cells were then added to DCs together with the same number of purified
naive HA-specific CD81 TCR Tg T cells. After a 3-d incubation, cells in
each plate were split into two 96-well V-bottomed plates to which 51Cr-
labeled target cells (P8151/2 HA518–527 peptide) were added. After a 4-h
incubation, 51Cr release was measured and percent peptide-specific lysis
was determined as described in Materials and Methods.
Figure 2. Effect of CD41 T cell help for direct priming CD81 CTLs in
vitro. Splenic DCs were incubated with a constant amount of the cognate
HA class II peptide and with serial dilutions of HA class I peptide over (A)
a high dose range or (B) a low dose range for 6–12 h and then washed.
Purified naive CD41 TCR Tg T cells (6.5) or non-Tg (N-Tg) CD41 T
cells were then added to DCs together with the same number of purified
naive CD81 TCR Tg T cells. After a 3-d incubation, a 51Cr-release assay
was performed and percent peptide-specific lysis was determined as in the
legend to Fig. 1.545 Lu et al.
wild-type BALB/c mice, the presence of Tg HA-specific
CD41 T cells significantly augmented the clonal expansion
of Tg HA-specific CD81 T cells, indicating that CD41 help
for CD81 T cell activation was indeed operative in this sys-
tem. The same adoptive transfer experiments into CD402/2
BALB/c mice demonstrated two important outcomes.
First, consistent with earlier reports, expansion of HA-spe-
cific CD81 T cells was significantly reduced in CD402/2
animals relative to wild-type (9). Nonetheless, a significant
CD4-dependent enhancement of HA-specific CD81 T cell
expansion was observed in the CD402/2 mice.
Similar results were observed in an examination of the
endogenous T cell repertoire having normal antigen-spe-
cific T cell precursor frequencies. For these experiments, we
switched to the influenza NP system because this antigen
generates more easily measurable CTL responses. By using
antibody depletion, we examined the contribution of CD41
T cells to CTL generation in vac-NP–infected wild-type
and CD402/2 mice. As shown in Fig. 6 A, we found that
while wild-type mice (CD401CD41) produced the stron-
gest Kd-restricted anti-NP CTL response, the presence of
CD41 T cells in CD402/2 mice (CD402CD41) still pro-
vided significant help for CTL induction. The same pattern
was also seen using IFN-g ELISPOT assay, which provides
a more quantitative measure of antigen-specific CD81 T
cell frequencies (Fig. 6 B). Taken together, these data
strongly indicate that CD41 T cells provide significant help
for induction of CTLs in vivo in the absence of CD40.
CD41 T Cells Deliver CD40-independent Help through
Sensitizing DCs and through Direct Lymphokine-mediated
CD4–CD8 Communication. The results obtained so far
demonstrate a CD40-independent component of T cell
help for CD81 CTL activation. We wished to examine
whether this pathway was mediated through an enhanced
capacity of DCs to activate CD81 T cells (“sensitization”),
a direct effect of the products of CD41 T cell activation on
the CD81 T cell response, or a combination of the two. This
distinction was achieved by modifying our in vitro system
to separate the CD41 T cell activation phase (phase I) from
the CD81 T cell activation phase (phase II). Enriched day 6
bone marrow–derived DCs were pulsed with a cell lysate
of CT26-HA and incubated with HA-specific CD41 T
cells or with an equal number of control non-Tg CD41 T
cells. 24–36 h later, CD41 T cells were either removed (by
magnetic separation; see Materials and Methods) or left in
place. After magnetic separation, contaminating CD41 T cells
were undetectable by FACS® analysis or by proliferation
([3H]thymidine incorporation) in response to pulsing DCs
with excess HA class II peptide (data not shown). After
CD41 T cell removal, DCs were washed free of lympho-
kines released during the phase I culture period, and were
then incubated with purified HA-specific CD81 T cells for
3 d, at which time HA-specific lysis was measured. We found
that only those DCs cultured with antigen-specific CD41
T cells were able to activate CD81 T cells, even after
CD41 T cells were removed (Fig. 7 A, groups 3 and 4).
Thus, a major component of CD40-independent help for
Figure 3. Comparison of the ability of wild-type DCs and CD402/2
DCs to activate naive CD41 T cells. Bone marrow–derived DCs from ei-
ther BALB/c wild-type or BALB/c CD402/2 mice were incubated with
(A) serial dilutions of CT26-HA lysate or (B) synthetic HA class II pep-
tide for 6–12 h and then washed. Purified naive Tg HA-specific CD41 T
cells were then added to the DCs. Supernatant was collected after 48 h for
lymphokine measurement, and cells were pulsed with [3H]thymidine (1
mCi/well) and harvested at 72 h. Thymidine incorporation was measured
as counts per minute. The levels of (C) IL-2 and (D) IFN-g in the super-
natant were measured by ELISA.
Figure 4. Comparison of wild-type DCs and
CD402/2 DCs for their ability to cross-prime
naive CD81 T cells in vitro. Bone marrow–
derived DCs (day 6) from either BALB/c wild-
type or BALB/c CD402/2 mice were incu-
bated with (A) serial dilutions of CT26-HA
lysate or (B) recombinant HA protein for 6–12 h
and then washed. Purified naive HA-specific
CD41 TCR Tg T cells (6.5) or non-Tg (N-Tg)
CD41 T cells were added to the DCs together
with the same number of purified naive HA-
specific CD81 TCR Tg T cells. After a 3-d in-
cubation, percent peptide-specific lysis was de-
termined as in the legend to Fig. 1.546 CD40-independent Pathways of T Cell Help
CTL priming involves DC sensitization. However, the
magnitude of CTL activity induced by those DCs was
greatly reduced compared with that generated by DCs left
in the presence of HA-specific CD41 T cells (Fig. 7 A,
groups 1 and 2). This suggests either that DC sensitization
wanes if CD41 T cell help is removed, or that signals pro-
vided by activated CD41 T cells directly augment CTL ac-
tivation as reflected in the maximal CTL response observed
when antigen-specific CD41 and CD81 T cells are present
simultaneously.
We next examined the extent to which supernatant from
activated HA-specific CD41 T cells could replace the
CD41 T cells themselves in providing help for CTL activa-
tion (Fig. 7 B). We first measured lymphokine profile in
the supernatant collected from overnight culture of HA an-
tigen–pulsed DCs and 6.5 Tg CD41 T cells. A significant
amount of IFN-g (150–200 pg/ml) and IL-2 (900–1,500
pg/ml) was detected, whereas the levels of TNF-a, IL-4,
and IL-12 were not measurable (data not shown). The su-
pernatant was added either to DCs in the DC sensitization
phase (phase I) or to the DCs after separation from CD41
T cells in the CD81 T cell activation phase (phase II). Al-
though supernatant could not substitute for CD41 T cells
in the sensitization of DCs (Fig. 7 B, group 7), its addition
to the culture during the period of CD81 T cell activation
restored the level of CTL killing to that observed when
CD41 T cells were present throughout (Fig. 7 B, groups 5
and 6). Interestingly, supernatant also enhanced the extent
of CTL activation achieved by unconditioned DCs (Fig. 7
B, group 6). There was no effect on CD81 T cells alone
(Fig. 7 B, group 8), indicating that the lymphokine effect
represented a true TCR (signal 1)–linked costimulatory
signal. Notably, CD402/2 DCs responded similarly to wild-
type DCs. Therefore, these data indicate that lymphokine-
mediated CD41–CD81 T cell communication represents a
component of CD40-independent help for CTL activation
that acts independently of the DC sensitization component.
Characteristics of Surface Molecules of Conditioned DCs.
Since CD41 T cell–conditioned DCs demonstrate an en-
hanced ability to activate antigen-specific CD81 T cells, it
was of interest to characterize expression of cell surface mol-
ecules known to be involved in T cell activation. Com-
pared with unconditioned DCs, the levels of MHC class I,
class II, B7-1/2, and CD11c were not significantly changed
on DCs conditioned for 24 h with CD41 T cells (Fig. 8).
There was a modest upregulation of CD40. Given that
CD41 T cell conditioning of DCs in vitro is CD40 inde-
pendent (see above), it is therefore likely that other mole-
cules account for the enhanced ability of CD41 condi-
tioned DCs to activate CD81 CTLs.
Discussion
The importance of CD41 help for CTL priming in vivo
has been well established (1, 2). Recent work has further
documented the importance of CD41 T cells for in vivo
cross-priming (3), antitumor immunity (28), and tolerance
induction (29). Evidence points to bone marrow–derived
APCs as the critical cells that process and present antigen to
naive CD4 and CD8 T cells in lymphatic tissue such as
spleen and draining lymph nodes (6, 30). Among bone mar-
row–derived APCs, DCs have proven to be the most potent
APCs because of their unique characteristic features: very
high MHC class II expression, costimulatory molecules B7-
1/2, and the ability to capture antigen at an immature stage
and efficiently present to T cells at a mature stage (31, 32).
Despite the availability of such potent APCs in vivo, it is
not well understood why generation of a CD81 CTL re-
sponse against many cell-based antigens requires additional
help from CD41 T cells. In vitro isolation of DCs from
spleen or bone marrow in the presence of GM-CSF makes
it possible to study these unique APCs in vitro (18, 19).
Early work showed that bone marrow–derived DCs or
macrophages did not need CD41 T cell help to cross-
present model antigens such as OVA (21–24), but only in
the presence of excessive concentration of antigen (.0.5
mg/ml). Indeed, we were able to confirm this CD4-inde-
pendent CD81 T cell activation in our current in vitro sys-
tem, which employs DCs as APCs and TCR Tg CD41
Figure 5. Adoptively transferred antigen-specific CD41 T cells can de-
liver help through the CD40-independent pathway in vivo. BALB/c
wild-type or CD402/2 mice (Thy1.21/1)  were injected intravenously
with 3 3 106 clonotypic HA-specific CD81 T cells (Thy1.11/2, cl4) with
or without 2.5 3 106 HA-specific clonotypic CD41 T cells (6.5). 24 h
later, mice were infected intraperitoneally with 107 PFU of vac-HA or
were left untreated. 4 d after infection, spleens were removed and cells
were double-stained with PE-conjugated anti-Thy1.1 antibody and
FITC-conjugated anti-CD8 antibody. The double-positive population
represents expansion of transferred clonotypic CD81 T cells. The
numbers shown above each graph represent the mean 6 SD of three in-
dependent determinations of percentages of Thy1.11CD81 cells. P , 0.01,
25 6 1.0 vs. 13.5 6 0.07% (wild-type); P , 0.005, 8.8 6 0.75 vs. 4.77 6
0.72% (CD402/2).547 Lu et al.
and CD81 T cells as helper and CTL responder cells, re-
spectively (Fig. 1). Most importantly, we observed potent
help from antigen-specific CD41 T cells for CTL activa-
tion when antigen is limiting. Similar enhancement by
CD41 help can also be seen when minimal class I peptide is
presented by DCs together with a constant amount of HA
class II peptide. Thus, it appears that help for CD81 T cell
activation is not an all-or-none phenomenon but rather
shifts the antigen dose–response curve. Taking this into ac-
count in a viral infection, it is possible that the need for
CD41 T cell help for CTL activation depends on the level
of the particular viral antigen expressed in vivo. Thus, viral
infections that lead to a high epitope density on bone mar-
row–derived APCs can lead to helper-independent activa-
tion of CD81 CTLs analogous to the high end of the anti-
gen dose–response curves in our in vitro system.
The mechanism of CD41 help for CTL activation was
originally felt to occur via provision of lymphokines (1).
This model was recently revised by studies that demon-
strated that the dominant T component of CD41 T cell
help is mediated through CD40 engagement on APCs (4,
13–15). CD40 ligation has been shown to result in activa-
tion and maturation of APCs (33, 34), which are then
thought to be responsible for their ability to drive a full ac-
tivation of naive CD81 T cells without need for direct
CD41–CD81 T cell communication (13). Development of
in vitro systems to study complex cell–cell interactions such
as the CD4–DC–CD8 interaction involved in helper cell
facilitation of CTL priming is critical in dissecting the mo-
lecular mechanisms that mediate cellular functions. The in
vitro system we describe here indeed confirmed the impor-
tance of helper cell sensitization of DCs central to the
“temporal bridge” model, but revealed a surprisingly im-
portant role for a CD40-independent pathway. Thus, DCs
from CD402/2 mice were equally capable of being sensi-
tized by CD41 helper cells as wild-type DCs, as assayed by
their ability to activate naive CD81 CTLs. The inability of
agonist anti-CD40 antibodies to replace any of this helper
cell function further suggests that CD40-independent helper
cell sensitization for DCs represents a major pathway. This
in vitro finding led us to develop systems to directly evalu-
ate the role of CD40-dependent versus CD40-independent
Figure 6. Endogenous CD41 T cells can also
deliver help through a CD40-independent path-
way in vivo. BALB/c wild-type or CD402/2
mice were either injected intraperitoneally with
antibody to CD4 (GK1.5) every other day for 1
wk or left untreated. After complete depletion
of CD41 T cells was confirmed by FACS®, the
mice were infected with 107 PFU of vac-NP.
(A) NP-specific CTL analysis. 7 d after infec-
tion, spleens were removed and splenocytes were
restimulated with NP-Kd peptide for 5–6 d. A
standard 4-h 51Cr-release assay was performed.
Percent specific lysis is shown. Background lysis
in the absence of peptide was ,1% for all E/T
ratios shown. Data shown are from an experi-
ment representative of three independent exper-
iments. (B) NP-specific IFN-g ELISPOT analy-
sis. Splenocytes were restimulated with or without
1 mg/ml of NP-Kd peptide in a 96-well filtration
plate previously coated with anti–IFN-g antibody. After overnight stimulation, the wells were washed and biotinylated IFN-g was added. After over-
night incubation at 48C, streptavidin-conjugated alkaline phosphatase was plated into each well and followed by addition of the substrate solution BCIP/
NBT. Peptide-specific IFN-g–positive spots are presented with the background subtracted.
Figure 7. Dissecting routes of CD41 T cell help for priming CD81 T
cells. (A) Bone marrow DCs (day 6, enriched) were incubated with
CT26-HA lysate in either a 24-well plate or a 96-well U-bottomed plate
for 6 h and washed. Purified 6.5 Tg CD41 T cells or non-Tg CD41 T
cells were then added to the DCs. After a 24–36-h incubation, superna-
tant in the 24-well plate was saved and CD41 T cells were removed from
DCs by Dynal magnetic beads (see Materials and Methods). Cells in the
96-well plate were washed, and CD41 T cells were left in place. Nonsep-
arated DCs (groups 1 and 2) or separated DCs (groups 3 and 4) were then
cultured with purified naive HA-specific Tg CD81 T cells in a 96-well
U-bottomed plate for 3 d. Percent peptide-specific lysis was determined
as in the legend to Fig. 1. (B) Separated DCs from CD41 T cells were
cultured with HA-specific Tg CD81 T cells for 3 d in the presence of su-
pernatant (100 ml) from activated CD41 T cell culture (groups 5 and 6).
Alternatively, supernatant was also added to DC cultures instead of CD41
T cells in phase I, and then washed twice before being cultured with na-
ive CD81 Tg T cells (group 7). Supernatant was also incubated with na-
ive Tg CD81 T cells (group 8). After a 3-d incubation, percent peptide-
specific lysis was determined as in the legend to Fig. 1.548 CD40-independent Pathways of T Cell Help
pathways of help for CTL activation in vivo. Two different
in vivo systems, one using adoptively transferred marked
Tg T cells and one evaluating responses mediated by the
endogenous repertoire, revealed a significant CD40-inde-
pendent pathway of help for CTL activation in addition to
the CD40-dependent pathway. Therefore, we believe that
dissection of the CD40-independent pathways in the in
vitro system will yield important information relevant to in
vivo CTL priming.
That there are multiple CD4 signals for DC activation is
not surprising, given the precedent set by CD4 activation
of other MHC class II1 immune cells such as B cells and
macrophages. B cells receive both CD40-dependent and
lymphokine-mediated signals from CD41 T cells during
antigen-dependent differentiation (35). In our preliminary
experiments, supernatants from activated CD41 cells failed
to replace CD41 help in the DC activation phase of the in
vitro system, suggesting that other membrane–membrane
receptor ligand interactions may constitute the CD40-inde-
pendent component. Recent in vivo experiments on the
importance of the TNF-related activation induced cyto-
kine (TRANCE)–TRANCE receptor interaction in medi-
ating CD40-independent immune responses to certain viral
infections (36, 37) indeed suggest that this novel TNF–
TNFR family pair may be a promising candidate for the
CD40-independent pathway of CD4-dependent DC acti-
vation revealed in our in vitro system. It is important to
note that the failure to replace CD41 help by supernatant
from activated CD41 T cells does not absolutely rule out
the involvement of lymphokines in the DC activation pro-
cess. It is quite possible that the lymphokine concentrations
in supernatant collected from DC–CD41 T cell cultures may
not be high enough to mediate effects generated by directed
secretion from a CD4 cell that is engaged with a DC.
An as yet unresolved question raised by our experiments
is whether the CD41 T cell effect on DC activation of CD81
CTLs occurs at the level of antigen processing, costimula-
tion, or both. The 2-log dose–response curve shift when
antigen was provided to DCs as cell lysate initially sug-
gested that CD4 sensitization of DCs may enhance process-
ing through the cross-priming pathway. However, the sig-
nificant dose–response curve shift seen when antigen is
provided as minimal class I peptide (thereby bypassing anti-
gen processing), together with the absence of an increase in
overall surface MHC class I levels, indicates that an impor-
tant component of DC sensitization involves expression of
costimulatory molecules capable of enhancing CD81 T cell
priming. Importantly, the finding that CD41 T cell activation
of DCs fails to increase B7 expression and IL-12 but is impor-
tant for the overall enhanced CTL activity indicates that an-
other as yet unidentified costimulatory molecule(s) plays an
important role in DC activation of CD8 CTLs.
Another component of CD41 help for CTLs revealed by
the in vitro system represents direct CD41–CD81 T cell
communication as demonstrated by a decrease in help for
CD81 T cell priming observed when the CD4–DC and
DC–CD8 phases were separated. In contrast to the DC ac-
tivation process, this component could be replaced by su-
pernatant from DC-activated CD41 T cells. Based on these
results, we propose an integrated model of CD41 help for
CD81 CTL activation as shown in Fig. 9. In addition to
the signal of CD40-dependent DC sensitization, our data
indicate two additional signals: CD40-independent DC
sensitization and direct CD41–CD81 T cell communica-
tion via lymphokines. However, it is not clear how these
three signaling components are interacting with each other.
Based on the fact that viral infection can sensitize DCs
without CD41 T cells (14), the findings that CD41 T cells
still provide significant help for the viral-induced CTL re-
sponses in the absence of CD40 reported here and else-
where (9) suggest that there are two different pathways of
CD41 help. One is the CD40-dependent pathway in which
CD41 T cells sensitize and mature DCs through engage-
ment of CD40 (primary CD41 help), and another is the
CD40-independent pathway, which takes place after DC
activation (secondary CD41 help). While virus can bypass
Figure 8. Characteristics of cell surface markers of conditioned versus unconditioned DCs. DCs separated from a 24-h coculture with HA-specific
CD41 T cells (Conditioned) or HA-nonspecific CD4 T cells (Unconditioned) were stained for the indicated cell surface molecules: MHC class I, MHC
class II, CD80/CD86, CD40, and CD11c. Solid line, primary antibody plus FITC- or PE-labeled secondary antibody. Broken line, isotype control pri-
mary antibody plus FITC- or PE-labeled secondary antibody.549 Lu et al.
the primary CD41 help, cell-based antigen requires CD41
T cells or anti-CD40 agonist antibody to cross-link CD40
on DCs for the initial activation (4, 15). The complete re-
placement of CD41 T cells for induction of CTLs in vivo
by cross-linking of CD40 on APCs seems to exclude re-
quirement of any secondary CD41 help such as secreting
lymphokines (4, 15). However, it is quite possible that
these systems used antigen at a high antigen dose range,
which may allow CD40-activated DCs to sufficiently drive
CD81 T cell activation without secondary CD41 help,
similar to what was observed in vitro when a high antigen
dose was provided. The effect of antigen dose on the anti-
gen presentation to CD81 T cells was also documented in
other in vivo systems (38, 39). Interestingly, our in vitro
system demonstrated complete independence of CD40 sig-
naling, suggesting that in vitro–cultured DCs may have dif-
ferentiated past the initial CD40-dependent activation stage
and are therefore subject to CD40-independent secondary
CD41 help.
Ridge et al. (14) have argued that a direct CD4–CD8
signaling pathway of CD41 help for CTL activation would
be inefficient, since it would require that CD41 and CD81
cells contact the same APC at the same time. However,
given recent evidence that DC–T cell interactions can be
extremely long-lasting (hours to days), the idea that anti-
gen-specific CD41 T cells and CD81 T cells may engage
the same DC for an overlapping segment of time is in fact
plausible. Ultimately, direct demonstration of the temporal
proximity of this three cell interaction in vivo must be
demonstrated to verify this notion experimentally. The abil-
ity to adoptively transfer marked antigen-specific CD41
and CD81 T cells, together with new techniques of in vivo
imaging, makes this an experimentally tractable question.
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